Evidence map›Paper›PMID 24084024›Full record

ArticleMolecules (Basel, Switzerland)2013

Promising low-toxicity of viologen-phosphorus dendrimers against embryonic mouse hippocampal cells.

Joanna Lazniewska, Anna Janaszewska, Katarzyna Miłowska, Anne-Marie Caminade, Serge Mignani, Nadia Katir, Abdelkrim El Kadib, Maria Bryszewska, Jean-Pierre Majoral, Teresa Gabryelak and 1 more

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.9field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Phosphorus Dendrimers as Nanotools against Cancers.Molecules (Basel, Switzerland) · 2020
    Review
  5. Article
  6. Bifunctional Phosphorus Dendrimers and Their Properties.Molecules (Basel, Switzerland) · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Joanna LazniewskaDepartment of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, Lodz 90236, Poland. aklajn@biol.uni.lodz.pl.
Anna Janaszewska
Katarzyna Miłowska
Anne-Marie Caminade
Serge Mignani
Nadia Katir
Abdelkrim El Kadib
Maria Bryszewska
Jean-Pierre Majoral
Teresa Gabryelak
Barbara Klajnert-Maculewicz
University of Łódź · PLCentre National de la Recherche Scientifique · FRMoroccan Foundation for Advanced Science, Innovation and Research · MA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A new class of viologen-phosphorus dendrimers (VPDs) has been recently shown to possess the ability to inhibit neurodegenerative processes in vitro. Nevertheless, in the Central Nervous Systems domain, there is little information on their impact on cell functions, especially on neuronal cells. In this work, we examined the influence of two VPD (VPD1 and VPD3) of zero generation (G0) on murine hippocampal cell line (named mHippoE-18). Extended analyses of cell responses to these nanomolecules comprised cytotoxicity test, reactive oxygen species (ROS) generation studies, mitochondrial membrane potential (ΔΨm) assay, cell death detection, cell morphology assessment, cell cycle studies, as well as measurements of catalase (CAT) activity and glutathione (GSH) level. The results indicate that VPD1 is more toxic than VPD3. However, these two tested dendrimers did not cause a strong cellular response, and induced a low level of apoptosis. Interestingly, VPD1 and VPD3 treatment led to a small decline in ROS level compared to untreated cells, which correlated with slightly increased catalase activity. This result indicates that the VPDs can indirectly lower the level of ROS in cells. Summarising, low-cytotoxicity on mHippoE-18 cells together with their ability to quench ROS, make the VPDs very promising nanodevices for future applications in the biomedical field as nanocarriers and/or drugs per se.

Indexed as

AnimalsApoptosisCatalaseCell Cycle CheckpointsCell LineCell ShapeCell SurvivalDendrimersDrug Evaluation, PreclinicalGlutathioneHippocampusMembrane Potential, MitochondrialMiceNeuronsOrganophosphonatesReactive Oxygen SpeciesCatalaseDendrimersGlutathioneOrganophosphonatesReactive Oxygen SpeciesViologens

Identifiers

PMID24084024
PMCPMC6270227
OpenAlexW2002801086

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.